SE9002671D0 - NEW PEPTIDES, DIAGNOSTIC ANTIGENES, USE OF THEM AND VACCINES - Google Patents

NEW PEPTIDES, DIAGNOSTIC ANTIGENES, USE OF THEM AND VACCINES

Info

Publication number
SE9002671D0
SE9002671D0 SE9002671A SE9002671A SE9002671D0 SE 9002671 D0 SE9002671 D0 SE 9002671D0 SE 9002671 A SE9002671 A SE 9002671A SE 9002671 A SE9002671 A SE 9002671A SE 9002671 D0 SE9002671 D0 SE 9002671D0
Authority
SE
Sweden
Prior art keywords
diagnostic
vaccines
antigenes
peptides
new peptides
Prior art date
Application number
SE9002671A
Other languages
Swedish (sv)
Other versions
SE470074B (en
SE9002671L (en
Inventor
J Blomberg
Original Assignee
Replico Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Replico Ab filed Critical Replico Ab
Priority to SE9002671A priority Critical patent/SE470074B/en
Publication of SE9002671D0 publication Critical patent/SE9002671D0/en
Priority to EP91915656A priority patent/EP0546031A1/en
Priority to PCT/SE1991/000542 priority patent/WO1992003475A1/en
Priority to AU84002/91A priority patent/AU649473B2/en
Publication of SE9002671L publication Critical patent/SE9002671L/en
Publication of SE470074B publication Critical patent/SE470074B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32711—Rhinovirus
    • C12N2770/32722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Peptides and a diagnostic antigen containing one of said peptides and having the ability to detect antibodies against at least one type of picornavirus and flavivirus are described. The use of said diagnostic antigen for diagnosing infections caused by picornavirus and/or flavivirus and for discriminating between false and true diagnosed HIV-1 p17 positive sera is also described, as well as vaccines against diseases caused by picornaviruses and/or flaviviruses.
SE9002671A 1990-08-16 1990-08-16 Method for diagnosis of picorene and / or flavivirus infection, peptides, diagnostic antigens and vaccine composition with these peptides SE470074B (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
SE9002671A SE470074B (en) 1990-08-16 1990-08-16 Method for diagnosis of picorene and / or flavivirus infection, peptides, diagnostic antigens and vaccine composition with these peptides
EP91915656A EP0546031A1 (en) 1990-08-16 1991-08-16 Enterovirus peptides
PCT/SE1991/000542 WO1992003475A1 (en) 1990-08-16 1991-08-16 Enterovirus peptides
AU84002/91A AU649473B2 (en) 1990-08-16 1991-08-16 Enterovirus peptides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9002671A SE470074B (en) 1990-08-16 1990-08-16 Method for diagnosis of picorene and / or flavivirus infection, peptides, diagnostic antigens and vaccine composition with these peptides

Publications (3)

Publication Number Publication Date
SE9002671D0 true SE9002671D0 (en) 1990-08-16
SE9002671L SE9002671L (en) 1992-02-17
SE470074B SE470074B (en) 1993-11-01

Family

ID=20380170

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9002671A SE470074B (en) 1990-08-16 1990-08-16 Method for diagnosis of picorene and / or flavivirus infection, peptides, diagnostic antigens and vaccine composition with these peptides

Country Status (4)

Country Link
EP (1) EP0546031A1 (en)
AU (1) AU649473B2 (en)
SE (1) SE470074B (en)
WO (1) WO1992003475A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4776075B2 (en) 1998-12-31 2011-09-21 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Modified HIVENV polypeptide
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
UY35418A (en) 2013-03-15 2014-10-31 Glaxosmithkline Biolog Sa Vaccine that provides protection against different human Picornaviruses.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT384363B (en) * 1982-10-05 1987-11-10 Immuno Ag METHOD FOR USE OF ANTIGENS REACTIVE PEPTIDES FOR THE PRODUCTION OF VACCINES ACTIVE AGAINST TBE VIRUS INFECTIONS
DE3650175T3 (en) * 1985-04-29 2007-09-06 Bio-Rad Laboratories, Inc., Hercules SYNTHETIC ANTIGENIC TO IDENTIFY AIDS.
JPH0768267B2 (en) * 1986-06-05 1995-07-26 財団法人阪大微生物病研究会 Flavivirus antigen
WO1988003032A1 (en) * 1986-10-27 1988-05-05 Fournier Maurielle J Diagnosis of and vaccine for japanese encephalitis virus and related viruses
ATE122055T1 (en) * 1987-03-20 1995-05-15 Immuno Ag DNA AND RNA MOLECULES OF THE WESTERN SUBTYPE OF TBE VIRUS, POLYPEPTIDES ENCODED BY THESE MOLECULES, AND THEIR USE.
JPH084508B2 (en) * 1987-09-16 1996-01-24 国立予防衛生研究所長 Recombinant vaccinia virus
GB8821077D0 (en) * 1988-09-08 1988-10-05 Wellcome Found Peptides

Also Published As

Publication number Publication date
WO1992003475A1 (en) 1992-03-05
AU649473B2 (en) 1994-05-26
EP0546031A1 (en) 1993-06-16
AU8400291A (en) 1992-03-17
SE470074B (en) 1993-11-01
SE9002671L (en) 1992-02-17

Similar Documents

Publication Publication Date Title
DK0610250T3 (en) Vaccine with porcine reproductive respiratory syndrome and diagnosis thereof
NO893894D0 (en) NON-A, NOK-B HEPATITVIRUS ANTIGEN PEPTID.
DK614987A (en) SYNTHETIC HTLV-III PEPTIDES, PREPARATIONS AND APPLICATIONS THEREOF
ATE109795T1 (en) HTLV-III ENCODING PEPTIDES.
EA200300336A1 (en) HIV PEPTIDES, ANTIGENES, VACCINE COMPOSITIONS, KIT FOR IMMUNO ANALYSIS AND METHOD OF DETECTING ANTIBODIES INDUCED BY HIV
ES2170152T3 (en) VIRUSES OF HEPATITIS G AND MOLECULAR CLONE OF THE SAME.
Sylvan et al. Prevalence of antibodies to hepatitis E virus among hemodialysis patients in Sweden
RUSSELL Immunopathologic mechanisms in the dengue shock syndrome
SE9002671L (en) NEW PEPTIDES, DIAGNOSTIC ANTIGENES, USE OF THEM AND VACCINES
NO950977L (en) New branched hydride and cluster peptides that are effective in diagnosing and detecting non-A, non-B hepatitis
Goh et al. Acute haemorrhagic conjunctivitis: seroepidemiology of coxsackievirus A24 variant and enterovirus 70 in Singapore
Nigro et al. Parvovirus infection in children with AIDS: high prevalence of B19-specific immunoglobulin M and G antibodies
KR970706300A (en) Recombinant protein of hepatitis E Pakistani strain and diagnosis method and vaccine using the same (RECOMBINANT PROTEINS OF A PAKISTANI STRAIN OF HEPATITIS E AND THEIR USE IN DIAGNOSTIC METHODS AND VACCINES)
DE68928933D1 (en) FIBER HEMAGGLUTININE BY B. PERTUSSIS
ES2094124T3 (en) IMMUNOLOGICAL TEST OF ANTIBODIES AGAINST HIV.
SE9101863D0 (en) PEPTIDES, DIAGNOSTIC ANTIGEN, VACCINE COMPOSITION AND PROCEDURES FOR SELECTING HIV STARMS
Nakajima et al. Demonstration of antigenic identity between purified equine infectious anemia virus and an antigen extracted from infected horse spleen
Stanley et al. Studies on Australian Strains of Coxsackie Virus (Groups A and B).
Brown et al. Fluorescent antibody responses of cases and contacts of hand, foot, and mouth disease
EP0250128A3 (en) Novel virus isolated from patients with aids
ATE540052T1 (en) NEW PEPTIDES REPRESENTING EPITOPES OF HUMAN HERPES VIRUS 8
SU1105188A1 (en) Method of diagnosis of acute stage of virus hepatitis
Mangiafico et al. Isolation and identification of Venezuelan equine encephalitis virus from a human in Panama.
RU93026692A (en) KIT FOR DIFFERENTIAL DIAGNOSIS OF OMSK HEMORRHAGIC FEVER AND Tick-borne Encephalitis
Setoguchi et al. Overlap and discrepancy between tests for anti-C1OO, anti-GOR and anti-CP9 in patients with chronic liver disease and inhabitants in Saga, Japan

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 9002671-7

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 9002671-7

Format of ref document f/p: F